Yunling Du

Effect of Cisternal and Ventricular Blood on Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage:

Jan Claassen, Gary L. Bernardini, Kurt T. Kreiter et al. · Stroke · 2001 · 728 citations

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Evan A. Stein, Scott Mellis, George D. Yancopoulos et al. · New England Journal of Medicine · 2012 · 659 citations · Full text

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon et al. · Journal of clinical lipidology · 2015 · 460 citations · Full text

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

Daniel Gaudet, Dean J. Kereiakes, James M. McKenney et al. · The American Journal of Cardiology · 2014 · 209 citations

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak et al. · European Heart Journal · 2016 · 194 citations · Full text